Altis Labs raises $25 million USD Series A to expand AI for cancer trials

Altis Labs has new funding to help give drug makers a better look into how treatments can affect more types of cancer. The news: The Toronto-based healthtech startup has closed a $25-million USD ($35-million CAD) Series A round to expand its AI-powered prognosis platform for clinical trials. The round was co-led by New York City-based biotech investor OrbiMed and Qiming Venture Partners USA, the US-based branch of Chinese investor Qiming Venture Partners.